Innovotech Inc.Pursuing the Greatest Opportunityin Microbiology Since Penicillin <br />On the Radar <br />1 December 2010<...
Forward Looking Statements<br />This presentation contains forward-looking statements that are predictive in nature and su...
Opportunity<br /><ul><li>Biofilms
The natural state of bacteria
Plaque on teeth
Scum in shower
Cause 80% of human infections
Up to 1000x more resistant
No antibiotics, disinfectants or diagnostics approved for biofilms
Involved in most cases of MRSA and  hospital-acquired infections</li></li></ul><li>Opportunity<br />New hospital superbugs...
  Market Opportunity<br />
Technology Platform<br />                      <br />DIAGNOSTIC Products:<br />bioFILM PA™, Gram +/-ve test<br />TREATMENT...
Path to Market - Healthcare<br />Product - bioFILM PA™ (Susceptibility test)<br /><ul><li>Validation
Clinical and health economic evaluation at University     of Alberta Cystic Fibrosis clinic – 3 lives saved
Sick Kids (Toronto) trial showing different antibiotic selections 71% of time compared to traditional testing
Partner with established market players
LevPharm Ltd – Hospital distributor in Israel
Upcoming SlideShare
Loading in …5
×

Innovotech Investor Presentation December 1, 2010

964 views

Published on

Innovotech Investor Presentation December 1, 2010

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
964
On SlideShare
0
From Embeds
0
Number of Embeds
29
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Innovotech Investor Presentation December 1, 2010

  1. 1. Innovotech Inc.Pursuing the Greatest Opportunityin Microbiology Since Penicillin <br />On the Radar <br />1 December 2010<br />
  2. 2. Forward Looking Statements<br />This presentation contains forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Forward-looking statements may include words such as “expects”, “plans”, “will”, “believes”, “estimates”, “intends”, “may”, and other words of similar meaning and may relate to future financial performance, business strategies, or safety and efficacy of unapproved products.<br />Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; the demand for new products and the impact of competitive products, service and pricing; availability and cost of raw materials; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defence; the Company’s exposure to lawsuits and other matters beyond the control of management.<br />
  3. 3. Opportunity<br /><ul><li>Biofilms
  4. 4. The natural state of bacteria
  5. 5. Plaque on teeth
  6. 6. Scum in shower
  7. 7. Cause 80% of human infections
  8. 8. Up to 1000x more resistant
  9. 9. No antibiotics, disinfectants or diagnostics approved for biofilms
  10. 10. Involved in most cases of MRSA and hospital-acquired infections</li></li></ul><li>Opportunity<br />New hospital superbugs proving resistant to antibiotics<br />A new hospital superbug resistant to antibiotics has been brought into the country by patients returning home after surgery abroad. <br />13 Aug 2009<br />Health Authorities Link 12 Deaths to Contaminated Meat<br />Twelve deaths in Canada have now been linked to listeriosis, according to federal health officials who said Monday the deaths are among 26 confirmed cases of an outbreak across the country stemming from contaminated meat.Monday, Aug. 25, 2008<br />Florida Orange Acres Fall as Farmers Cut Sick Trees<br />Orange-crop acreage in Florida, the world's second-biggest producer, fell to a 24-year low as growers removed trees to slow the spread of disease affecting citrus crops, the U.S Department of Agriculture said.<br />Thursday, September 23, 2010<br />
  11. 11. Market Opportunity<br />
  12. 12. Technology Platform<br />                      <br />DIAGNOSTIC Products:<br />bioFILM PA™, Gram +/-ve test<br />TREATMENT Products:<br />Agress®, Sani-Lux™,AgreGuard™<br />
  13. 13. Path to Market - Healthcare<br />Product - bioFILM PA™ (Susceptibility test)<br /><ul><li>Validation
  14. 14. Clinical and health economic evaluation at University of Alberta Cystic Fibrosis clinic – 3 lives saved
  15. 15. Sick Kids (Toronto) trial showing different antibiotic selections 71% of time compared to traditional testing
  16. 16. Partner with established market players
  17. 17. LevPharm Ltd – Hospital distributor in Israel
  18. 18. Regulatory
  19. 19. Health Canada approval
  20. 20. Research Use Only provisions in US</li></li></ul><li>Path to Market - Agriculture<br />Product - Agress® (Seed treatment and Plant Spray)<br /><ul><li>Validation</li></ul>Field trials – Streptomycin replacement<br /> Anti bacterial and anti-fungal activity<br /> Cost competitive and environmentally friendly<br /> Effective with existing products<br /><ul><li>Partner with established market players</li></ul>Syngenta – largest seed treatment company in the world<br /><ul><li>Regulatory
  21. 21. Ready for EPA submission</li></li></ul><li>Competition<br /><ul><li>Competition is from traditional methods</li></ul>Established industries, little innovation<br /><ul><li>Difficulties dealing with anti-microbial resistance
  22. 22. Environmental concerns
  23. 23. For bioFILM PA™
  24. 24. Empirical (educated guess)
  25. 25. For Agress®
  26. 26. Streptomycin</li></li></ul><li>Milestones<br />Revenue (000,000)<br />- EPA Approval (Pulse, Horticulture, Potatoes)<br />- EPA Application (Foliar)<br />- EU Application (Pulse & Other)<br />- Sick Kids trial complete<br />- Hlth Canada approval for Gram +/-ve test<br />- Marketing partner<br />EU Approval Gram +/-ve test<br />EPA Application<br /> (Pulse, Horticulture, Potatoes)<br />- PMRA Application (Pulse)<br />FDA approval for Gram +/-ve test; initiate trial<br />
  27. 27. History<br /><ul><li>2003
  28. 28. 2004
  29. 29. 2006
  30. 30. 2007
  31. 31. 2010</li></ul>- Began trading on the Toronto Venture Exchange (TSX-V: IOT)<br />- Completed Qualifying Transaction by acquiring University of Calgary technology<br />- Amalgamation of Innovotech and MBEC BioProducts<br />- Consolidation of operations in Edmonton<br />- 21 employees in 3600 sq. ft. facility<br />- Two products in advanced stages of development<br />
  32. 32. People - Board<br />Lorne Babiuk, PhD<br />Kerry Brown , CA<br />Bruce Hirsche, LLM<br />Corporate Secretary <br />Wolfgang Muhs, PhD<br />Chairman of the Board<br />John Pinsent , CA<br />Gerard Tertzakian, PhD<br />James Timourian, PhD<br />Chief Financial Officer<br /><ul><li>Vice President Research, University of Alberta. Former-Director, VIDO, University of Saskatchewan, a renowned vaccine development institute.
  33. 33. Former-Chairman, Foundation Equity Corporation, a successful technology venture capital firm.
  34. 34. Partner with Parlee McLaws LLP, specializing in intellectual property and technology development.
  35. 35. Executive in pharmaceutical manufacturing at Laporte PLC, Degussa GmbH and Rhodia Pharma Solutions. CEO of Raylo Chemicals.
  36. 36. Founding Partner, St Arnaud Pinsent, Steman a technology-focused chartered accounting firm. Former Director of Technology at Ernst and Young LLP.
  37. 37. Experience in the creation, management, and financing of knowledge-based companies. Former-Chair & CEO of Innovotech, Raylo Chemicals and Cytovax Biotechnologies.
  38. 38. Former CFO at Raylo Chemicals. Former Chairman of the Board at Ricon Resins Inc. Serial investor and board member in over 15 early-stage technology companies. </li></li></ul><li>People – Senior Management<br /><ul><li>Former senior manager at Glaxo SmithKline Inc, McKesson Canada and Canada Safeway Pharmacies Ltd with experience in operations and marketing spanning biotechnology, pharmaceutical manufacturing and distribution, and retail pharmacy.
  39. 39. World recognized biofilm expert. Experienced researcher and entrepreneur holding over 35 patents in medical and veterinary science and over 170 published papers. Inventor of the MBEC Assay™ and founder of MBEC Biofilm Technologies.
  40. 40. Former CFO at Raylo Chemicals. Former Chairman of the Board at Ricon Resins Inc. Serial investor and board member in over 15 early-stage technology companies.</li></ul>Ken Boutilier, MBA<br />President and CEO<br />Merle Olson, DVM<br />Research Director<br />Jim Timourian, PhD<br />Chief Financial Officer<br />
  41. 41. Product Pipeline<br />One platform technology – many products<br />Phase <br />of Development<br />Market <br />Introduction<br />Regulatory<br />Research <br />&<br /> Development<br />bioFILM PA™<br />Agress®<br />Sani-Lux™<br />Gram +/-ve test<br />AgreGuard™<br />Product<br />*AgreGuard™ is a Silver technology for coating catheters; Sani Lux™ is a hard surface disinfectant<br />
  42. 42. Financial Highlights<br /><ul><li>Expected revenue for 2010 - $1.5M
  43. 43. Low overheads
  44. 44. R&D expenditures - $550,000*
  45. 45. Burn rate - $82,000/month
  46. 46. Cash - $936,000*
  47. 47. Shares outstanding – 24M*</li></ul>* As of September 30, 2010<br />
  48. 48. Summary<br /><ul><li>Innovotech is a pioneer in the field of biofilm product development</li></ul>Medical, agricultural and industrial issues:<br /><ul><li>World’s first biofilm susceptibility test
  49. 49. “Green”, and effective agricultural product
  50. 50. Strong pipeline based on a single technology platform
  51. 51. Revenue</li></ul>“All current microbiology may have to be reinvented <br />to meet the needs of biofilm microbiology.” <br />
  52. 52. Contact Information<br />Ken Boutilier, President <br />Innovotech Inc. <br />ken.boutilier@innovotech.ca<br />Ph: 780-448-0585 ext 221<br />Fax: 780-424-0941<br />

×